Cardioprotective effects of angiotensin receptor-neprilysin inhibitors in the real world

Cardioprotective effects of angiotensin receptor-neprilysin inhibitors - Cardioprotective effects of angiotensin receptor-neprilysin inhibitors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043197

Enrollment

360

Registered

2021-02-01

Start date

2021-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients undergoing treatment for heart failure in daily practice who are scheduled to change from angiotensin-converting enzyme inhibitors or angiotensin II receptor blocker to ARNI

Exclusion criteria

Exclusion criteria: Patients already receiving ARNI Patients who do not change as a result of consideration Patients with severe liver dysfunction (Child-Pugh classification C)

Design outcomes

Primary

Measure	Time frame
Change in NT-proBNP(BNP)(after 6 months or later)	—

Secondary

Measure	Time frame
Changes in troponin I(T), cardiac function(chest X-ray, electrocardiogram and echocardiography), renal function, inflammation, and the presence or absence of major cardiovascular events(MACE)(after 6 months or later)	—

Countries

Japan

Contacts

Public ContactYuhei Shiga

Fukuoka University Hospital Department of Cardiology

yuheis@fukuoka-u.ac.jp0928011011

Outcome results